Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Website: aerovatetx.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -145.2% (LTM)

Entry Point: Share price is 90.1% higher than minimum and 91.3% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: AVTE
Share price, USD:  (-1.5%)2.68
year average price 4.50  


year start price 21.75 2024-04-27

max close price 24.62 2024-06-14

min close price 1.41 2024-06-18

current price 2.68 2025-04-26
Common stocks: 24 410 400

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 65
Net Debt ($m): -28
EV (Enterprise Value): 37
Price to Book: 0.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-04-07prnewswire.com

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

2024-12-28businesswire.com

AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders

2024-11-05globenewswire.com

INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE

2024-11-03prnewswire.com

INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE

2024-11-01prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders

2024-10-31businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

2024-06-20globenewswire.com

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

2024-06-18zacks.com

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

2024-06-17globenewswire.com

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

2024-05-21globenewswire.com

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-12 2024-05-13 2024-03-25 2023-11-13 2023-08-14 2023-05-15 2023-03-29 2022-11-14 2022-08-15
acceptedDate 2024-11-12 16:40:34 2024-08-12 16:31:10 2024-05-13 16:57:50 2024-03-25 16:15:50 2023-11-13 08:16:11 2023-08-14 08:16:01 2023-05-15 16:11:52 2023-03-29 17:04:43 2022-11-14 07:50:45 2022-08-15 08:00:54
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 136 000 0 0 0 0 0 0
costOfRevenue 0 28 000 28 000 28 000 25 000 22 000 0 0 0 0
grossProfit 0 -28 000 -28 000 108 000 -25 000 -22 000 0 0 0 0
grossProfitRatio 0 0 0 0.794 0 0 0 0 0 0
researchAndDevelopmentExpenses 10M 21M 20M 18M 17M 16M 13M 12M 11M 8M
generalAndAdministrativeExpenses 7M 5M 5M 4M 4M 4M 4M 4M 3M 4M
sellingAndMarketingExpenses 0 0 -28 000 -28 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 7M 5M 5M 4M 4M 4M 4M 4M 3M 4M
otherExpenses 0 0 -3000 1000 1000 -1000 -1000 -77 000 0 0
operatingExpenses 17M 26M 25M 22M 21M 20M 18M 16M 14M 12M
costAndExpenses 17M 26M 25M 22M 21M 20M 18M 16M 14M 0
interestIncome 1M 1M 1M 2M 2M 1M 1M 932 000 560 000 230 000
interestExpense 0 0 0 1M 0 0 -1M -1M 560 000 0
depreciationAndAmortization 218 000 28 000 28 000 28 000 25 000 22 000 21 000 20 000 20 000 -4000
ebitda -17M -26M -25M -22M -21M -20M -18M -16M -14M -12M
ebitdaratio 0 0 0 -162.044 0 0 0 0 0 0
operatingIncome -17M -26M -25M -22M -21M -20M -18M -16M -14M -12M
operatingIncomeRatio 0 0 0 -162.25 0 0 0 0 0 0
totalOtherIncomeExpensesNet 1M 1M 1M 2M 2M -1000 1M 855 000 564 000 224 000
incomeBeforeTax -16M -25M -23M -20M -20M -19M -17M -15M -14M -12M
incomeBeforeTaxRatio 0 0 0 -149.684 0 0 0 0 0 0
incomeTaxExpense 0 0 -15 276 56 000 -25 000 -1M -1M 25 000 -564 000 0
netIncome -16M -25M -23M -20M -20M -19M -15M -15M -13M -12M
netIncomeRatio 0 0 0 -150.096 0 0 0 0 0 0
eps -0.56 -0.86 -0.83 -0.74 -0.71 -0.76 -0.62 -0.61 -0.53 -0.49
epsdiluted -0.56 -0.86 -0.83 -0.74 -0.71 -0.76 -0.62 -0.61 -0.53 -0.49
weightedAverageShsOut 29M 29M 28M 28M 28M 25M 25M 24M 24M 24M
weightedAverageShsOutDil 29M 29M 28M 28M 28M 25M 25M 24M 24M 24M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-12 2024-05-13 2024-03-25 2023-11-13 2023-08-14 2023-05-15 2023-03-29 2022-11-14 2022-08-15
acceptedDate 2024-11-12 16:40:34 2024-08-12 16:31:10 2024-05-13 16:57:50 2024-03-25 16:15:50 2023-11-13 08:16:11 2023-08-14 08:16:01 2023-05-15 16:11:52 2023-03-29 17:04:43 2022-11-14 07:50:45 2022-08-15 08:00:54
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 31M 31M 9M 23M 32M 61M 27M 22M 22M 27M
shortTermInvestments 58M 73M 90M 99M 103M 89M 92M 107M 120M 125M
cashAndShortTermInvestments 89M 104M 99M 122M 135M 150M 119M 129M 143M 152M
netReceivables 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 2M 7M 4M 2M 567 000 2M 266 000 295 000 331 000 1M
totalCurrentAssets 91M 111M 103M 124M 138M 152M 121M 131M 145M 153M
propertyPlantEquipmentNet 273 000 853 000 985 000 902 000 1M 1M 1M 1M 1M 2M
goodwill 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 81 000 81 000 3M 2M 2M 2M 3M 3M 1M 731 000
totalNonCurrentAssets 354 000 934 000 4M 3M 3M 3M 4M 4M 3M 2M
otherAssets 0 0 1 0 0 0 0 0 0 0
totalAssets 91M 112M 107M 127M 141M 156M 124M 135M 148M 156M
accountPayables 908 000 4M 3M 2M 4M 6M 5M 3M 5M 2M
shortTermDebt 459 000 950 000 445 000 420 000 451 000 379 000 373 000 385 000 379 000 347 000
taxPayables 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 10M 7M 0 0 0 0
otherCurrentLiabilities 9M 12M 12M 15M 439 000 583 000 6M 5M 3M 1M
totalCurrentLiabilities 10M 17M 16M 18M 15M 13M 11M 8M 8M 4M
longTermDebt 81 000 206 000 329 000 255 000 358 000 476 000 591 000 705 000 800 000 862 000
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 70 000 70 000 69 999 69 999 70 000 69 000 70 000 71 000 -4M 13 000
totalNonCurrentLiabilities 151 000 276 000 398 999 324 999 428 000 545 000 661 000 776 000 813 000 875 000
otherLiabilities 0 0 1 1 0 0 0 0 0 0
capitalLeaseObligations 540 000 681 000 329 000 255 000 809 000 855 000 964 000 1M 1M 1M
totalLiabilities 10M 17M 16M 18M 15M 14M 11M 9M 9M 5M
preferredStock 0 0 0 0 0 0 0 0 0 0
commonStock 3000 3000 3000 3000 3000 3000 2000 2000 2000 2000
retainedEarnings -228M -211M -187M -163M -143M -123M -104M -88M -73M -59M
accumulatedOtherComprehensiveIncomeLoss 0 -83 000 -33 000 237 000 -195 000 -223 000 -201 000 -466 000 -771 000 -785 000
othertotalStockholdersEquity 308M 306M 278M 273M 269M 266M 218M 215M 213M 211M
totalStockholdersEquity 80M 94M 91M 109M 126M 142M 113M 127M 139M 151M
totalEquity 80M 94M 91M 109M 126M 142M 113M 127M 139M 151M
totalLiabilitiesAndStockholdersEquity 91M 112M 107M 127M 141M 156M 124M 135M 148M 156M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 91M 112M 107M 127M 141M 156M 124M 135M 148M 156M
totalInvestments 58M 73M 90M 99M 103M 89M 92M 107M 120M 0
totalDebt 540 000 681 000 774 000 675 000 809 000 855 000 964 000 1M 1M 1M
netDebt -31M -30M -8M -23M -31M -60M -26M -21M -21M -26M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-12 2024-05-13 2024-03-25 2023-11-13 2023-08-14 2023-05-15 2023-03-29 2022-11-14 2022-08-15
acceptedDate 2024-11-12 16:40:34 2024-08-12 16:31:10 2024-05-13 16:57:50 2024-03-25 16:15:50 2023-11-13 08:16:11 2023-08-14 08:16:01 2023-05-15 16:11:52 2023-03-29 17:04:43 2022-11-14 07:50:45 2022-08-15 08:00:54
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -16M -25M -23M -20M -20M -19M -17M -15M -14M -12M
depreciationAndAmortization -2M 28 000 28 000 28 000 25 000 22 000 21 000 20 000 20 000 -4000
deferredIncomeTax 0 0 0 -4M 0 0 0 0 0 0
stockBasedCompensation 2M 4M 4M 3M 3M 3M 2M 2M 1M 2M
changeInWorkingCapital 3M 1M -4M 3M 1M 2M 3M -1M 3M 6M
accountsReceivables 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0
accountsPayables -3M 948 000 835 000 -1M -2M 773 000 2M -2M 2M 875 000
otherWorkingCapital 6M 193 000 -5M 4M 4M 892 000 1M 743 000 399 000 0
otherNonCashItems -3M -692 000 3M 3M -808 000 -639 000 -671 000 -586 000 -292 000 -11M
netCashProvidedByOperatingActivities -16M -20M -24M -15M -16M -15M -11M -15M -10M -15M
investmentsInPropertyPlantAndEquipment 0 0 0 -64 000 -32 000 -30 000 -16 000 -4000 -33 000 -158 000
acquisitionsNet 0 0 0 -5712 13 098 -4013 0 0 0 0
purchasesOfInvestments -5M 0 -15M -28M -48M -33M -16M -50M -26M -72M
salesMaturitiesOfInvestments 21M 18M 24M 34M 35M 37M 31M 65M 30M 60M
otherInvestingActivites 0 0 9M 5712 -13 098 4013 0 0 0 0
netCashUsedForInvestingActivites 16M 18M 9M 6M -13M 4M 15M 14M 5M -12M
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued -1M 24M 471 000 463 000 20 000 45M 0 150 000 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 22 000 24M -233 000 463 -75 000 0 223 000 207 000 37 000 2000
netCashUsedProvidedByFinancingActivities 22 000 24M 471 000 463 000 20 000 45M 223 000 357 000 37 000 2000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0
netChangeInCash 46 000 22M -14M -9M -29M 34M 4M -22 000 -5M -680 000
cashAtEndOfPeriod 31M 31M 9M 23M 32M 61M 27M 22M 22M 27M
cashAtBeginningOfPeriod 31M 9M 23M 32M 61M 27M 22M 22M 27M 28M
operatingCashFlow -16M -20M -24M -15M -16M -15M -11M -15M -10M -15M
capitalExpenditure 0 0 0 -64 000 -32 000 -30 000 -16 000 -4000 -33 000 -158 000
freeCashFlow -16M -20M -24M -15M -16M -15M -11M -15M -10M -15M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-10-31 11:00 ET
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
2024-07-08 12:00 ET
Aerovate Therapeutics to Explore Strategic Alternatives
2024-06-21 18:00 ET
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
2024-06-17 12:32 ET
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
2024-05-21 20:15 ET
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
2024-05-13 20:30 ET
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
2024-03-27 13:20 ET
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
2024-03-25 20:10 ET
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
2024-03-06 13:00 ET
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
2023-11-20 21:45 ET
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
2023-11-13 13:00 ET
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
2023-08-14 12:00 ET
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
2023-07-11 21:00 ET
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
2023-06-01 12:00 ET
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
2023-05-22 17:15 ET
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
2023-05-15 20:05 ET
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
2023-03-29 20:50 ET
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
2023-03-02 13:00 ET
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
2023-01-23 13:00 ET
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
2022-11-17 12:45 ET
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
2022-11-14 12:45 ET
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
2022-10-18 12:00 ET
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
2022-08-15 11:50 ET
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
2022-06-02 12:00 ET
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
2022-05-16 21:15 ET
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
2022-05-16 12:00 ET
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
2022-03-30 20:45 ET
Aerovate Therapeutics Announces Full-Year 2021 Financial Results
2022-03-02 13:00 ET
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference
2021-12-15 13:00 ET
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
2021-11-15 13:00 ET
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results
2021-09-17 12:00 ET
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
2021-08-16 12:00 ET
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results
2021-07-19 12:00 ET
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
2021-07-02 20:01 ET
Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2021-06-30 02:59 ET
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2025-04-25 00:00 ET
Aerovate Therapeutics, Inc. reported for 2025 q1
SEC form 10
2025-03-27 07:30 ET
Aerovate Therapeutics, Inc. reported for 2024 q4
SEC form 10
2025-03-27 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q4
SEC form 10
2024-11-12 16:40 ET
Aerovate Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-12 16:31 ET
Aerovate Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-08-12 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-13 16:57 ET
Aerovate Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-13 16:39 ET
Aerovate Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-13 16:39 ET
Aerovate Therapeutics, Inc. published news for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-25 16:15 ET
Aerovate Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-25 16:12 ET
Aerovate Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-25 16:12 ET
Aerovate Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-25 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-13 08:16 ET
Aerovate Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-13 08:03 ET
Aerovate Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-14 08:16 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-14 08:10 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-11 17:04 ET
Aerovate Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-11 17:03 ET
Aerovate Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-21 17:14 ET
Aerovate Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-15 16:11 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-15 16:08 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-19 16:31 ET
Aerovate Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-05 16:32 ET
Aerovate Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-29 17:04 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-29 16:52 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-29 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 10
2022-11-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-08-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-05-16 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-03-30 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q4
SEC form 10
2021-11-15 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-08-16 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q2